Skip to content
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Neurology

Long-Term Monitoring and Emergency Signs

At a Glance

For people with RRMS, MRI monitoring usually includes a new baseline scan about 3–6 months after starting treatment, a follow-up scan 6–12 months later, and ongoing scans based on stability. Sudden one-sided weakness, facial droop, speech trouble, seizures, or severe breathing or allergic symptoms require emergency care.

Living with RRMS means shifting from a “search for a diagnosis” to a “strategy of surveillance.” Because many changes in MS happen silently on an MRI before they cause physical symptoms, regular monitoring is your best tool for ensuring your treatment is working. This phase of care is about staying ahead of the disease while knowing exactly when to raise the alarm [1][2].

Your MRI Monitoring Schedule

Once you start a new Disease-Modifying Therapy (DMT), your doctor will use a series of “snapshots” to track its effectiveness. While every medication and clinic practice can vary, a typical surveillance framework often follows this pattern:

  • The Re-Baseline Scan (e.g., 3–6 Months): This is perhaps the most important scan. It takes a few months for most DMTs to become fully effective. This scan establishes a new “baseline” of what your brain looks like while on the drug [1].
  • The Follow-Up (e.g., 6–12 Months Later): A second scan is typically done 6 to 12 months after your re-baseline. Your doctor will compare these two scans to see if any new activity has occurred while the drug was at full strength [1].
  • Maintenance: If your disease is stable, you may move to an annual MRI of the brain. Spinal cord surveillance or the use of contrast (gadolinium) is individualized and not universally required at every follow-up scan [1][3].

Addressing “Scan Anxiety”

It is perfectly normal to feel “scanxiety”—the mix of dread and nervousness that builds up before an MRI. Remember that a scan showing a new lesion is not a “failure” on your part; it is a vital piece of data that tells your team it may be time to adjust your strategy [4]. Communicating your anxiety to the technologist, using relaxation techniques, or arranging a prompt follow-up call to review results can help ease the psychological burden.

Distinguishing Fluctuations from Emergencies

Most day-to-day changes in how you feel—like a brief tingle in your fingers or a tired afternoon—are routine fluctuations. However, because you are taking medications that modify your immune system, there are specific situations that require medical attention.

When to Seek Emergency Care (Call 911 / Go to ER)

Go to the emergency room immediately if you experience sudden symptoms that could indicate a stroke or severe systemic reaction:

  • Sudden weakness on one side of your body, facial droop, or inability to speak.
  • Severe breathing difficulty or a seizure.
  • Infusion Reactions: During or shortly after an infusion, seek immediate help for throat swelling, difficulty breathing, widespread hives, or feeling like you might faint [5].

When to Call Your Neurology Clinic Promptly

Contact your clinic directly (do not wait for your next appointment) if you experience:

  • A “Different” Neurological Change: Any new symptom that is progressive, disabling, or feels completely different from your typical MS [6][7].
  • Signs of PML: If you are on natalizumab or an S1P modulator (like fingolimod), be alert for progressive clumsiness, vision changes in both eyes, or cognitive “fog” that gets worse day by day. These can be early signs of Progressive Multifocal Leukoencephalopathy (PML), a rare but serious brain infection [8][9].
  • Severe Infection: While on immunosuppressants, persistent productive coughs, painful urination, or unexplained systemic illness need prompt assessment. Note that some immunosuppressed people may not mount a high fever [10][11].
  • The Risk of “Rebound”: If you must stop taking an S1P modulator (like fingolimod or siponimod), it is critical to do so only under strict medical supervision. Abruptly stopping these drugs can occasionally cause a “rebound” effect—a sudden, severe flare of MS activity 2 to 4 months after the last dose. Always follow your prescriber’s transition plan [12][13][7].

Summary: When to Wait vs. When to Act

  • Routine: Symptoms that last minutes or hours and go away (like heat-related fatigue) [14].
  • Prompt Clinic Call: A possible “true relapse”—new symptoms lasting more than 24 hours (like a new numb patch on your leg), or any concerning signs of infection [14].
  • Emergency (Go to ER): Sudden confusion, inability to speak, facial droop, severe breathing difficulty, or severe allergic reactions [6][10].

Common questions in this guide

What MRI schedule is typical after I start an RRMS disease-modifying treatment?
Many clinicians obtain a new baseline brain MRI about 3 to 6 months after starting a disease-modifying therapy, followed by another scan 6 to 12 months later. If the disease is stable, yearly brain MRI may follow, but the exact schedule, spinal imaging, and use of contrast depend on your treatment and clinical situation.
Which symptoms mean I should call 911 or go to the emergency room?
Call 911 or go to the emergency room for sudden one-sided weakness, facial droop, inability to speak, severe breathing difficulty, or a seizure. During or soon after an infusion, throat swelling, difficulty breathing, widespread hives, or feeling faint can signal a severe reaction and requires immediate help.
When should I contact my neurology clinic about a new MS symptom?
Do not wait if a symptom is progressive, disabling, sudden, or unlike your usual MS. A new symptom lasting more than 24 hours may represent a relapse and should prompt a clinic call, and signs of infection such as a persistent productive cough, painful urination, or unexplained illness also need prompt assessment.
What are the warning signs of PML in someone with RRMS?
If you take natalizumab or an S1P modulator such as fingolimod, contact your neurology clinic promptly for worsening clumsiness, vision changes in both eyes, or cognitive fog that progresses day by day. PML is a rare but serious brain infection, so do not wait for a routine appointment.
Can stopping fingolimod or siponimod suddenly cause an MS rebound?
Yes. Abruptly stopping an S1P modulator such as fingolimod or siponimod can occasionally lead to a severe return of MS activity about 2 to 4 months later. Stop or switch these medicines only with a prescriber's transition plan.
How can I tell a routine MS fluctuation from a possible relapse?
Symptoms that last only minutes or hours and then resolve, such as heat-related fatigue, are often routine fluctuations. A new symptom that lasts more than 24 hours, especially a new numb area or disabling change, should prompt a call to your neurology team.
What can I do if MRI scans make me anxious?
Tell the MRI technologist about your anxiety, use relaxation techniques, and arrange a prompt follow-up call to review the results. A new lesion is information for your care team and is not a personal failure.

Get notified when new evidence is published on relapsing-remitting multiple sclerosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (14)
  1. 1

    Evolving role of MRI in optimizing the treatment of multiple sclerosis: Canadian Consensus recommendations.

    Arnold DL, Li D, Hohol M, et al.

    Multiple sclerosis journal - experimental, translational and clinical 2015; (1()):2055217315589775 doi:10.1177/2055217315589775.

    PMID: 28607695
  2. 2

    NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.

    Sormani MP, Muraro PA, Saccardi R, Mancardi G

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(2)):201-204 doi:10.1177/1352458516645670.

    PMID: 27207454
  3. 3

    Evidence-based guidelines: MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis--establishing disease prognosis and monitoring patients.

    Wattjes MP, Rovira À, Miller D, et al.

    Nature reviews. Neurology 2015; (11(10)):597-606 doi:10.1038/nrneurol.2015.157.

    PMID: 26369511
  4. 4

    Measuring treatment response to advance precision medicine for multiple sclerosis.

    Calabresi PA, Kappos L, Giovannoni G, et al.

    Annals of clinical and translational neurology 2021; (8(11)):2166-2173 doi:10.1002/acn3.51471.

    PMID: 34704393
  5. 5

    Post-infusion observation of patients with multiple sclerosis receiving natalizumab: Is it necessary?

    Bafrani MA, Ahmadi NS, Idjadi FZ, et al.

    Multiple sclerosis and related disorders 2026; (107()):106995 doi:10.1016/j.msard.2026.106995.

    PMID: 41587505
  6. 6

    Neuropsychological Disability in the Case of Natalizumab-Related Progressive Multifocal Leukoencephalopathy.

    Lo Buono V, D'Aleo G, Cammaroto S, et al.

    Medicina (Kaunas, Lithuania) 2022; (58(4)) doi:10.3390/medicina58040551.

    PMID: 35454389
  7. 7

    Extensive white matter lesions after 2 years of fingolimod: Progressive multifocal leukoencephalopathy or MS relapse?

    Boudot de la Motte M, Louapre C, Bertrand A, et al.

    Multiple sclerosis (Houndmills, Basingstoke, England) 2017; (23(4)):614-616 doi:10.1177/1352458516682858.

    PMID: 28273764
  8. 8

    Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

    Pavlovic D, Patera AC, Nyberg F, et al.

    Therapeutic advances in neurological disorders 2015; (8(6)):255-73 doi:10.1177/1756285615602832.

    PMID: 26600871
  9. 9

    Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.

    Wijburg MT, Kleerekooper I, Lissenberg-Witte BI, et al.

    JAMA neurology 2018; (75(7)):827-833 doi:10.1001/jamaneurol.2018.0094.

    PMID: 29532061
  10. 10

    Disseminated tuberculosis associated with fingolimod treatment in a patient with multiple sclerosis.

    Ong S, Kibbler J, Maxwell G, Steer J

    BMJ case reports 2024; (17(1)) doi:10.1136/bcr-2023-255011.

    PMID: 38171639
  11. 11

    Infection Mitigation Strategies for Multiple Sclerosis Patients on Oral and Monoclonal Disease-Modifying Therapies.

    Smith TE, Kister I

    Current neurology and neuroscience reports 2021; (21(7)):36 doi:10.1007/s11910-021-01117-y.

    PMID: 34009478
  12. 12

    Case Report: Persisting Lymphopenia During Neuropsychiatric Tumefactive Multiple Sclerosis Rebound Upon Fingolimod Withdrawal.

    Koska V, Förster M, Brouzou K, et al.

    Frontiers in neurology 2021; (12()):785180 doi:10.3389/fneur.2021.785180.

    PMID: 34777236
  13. 13

    Severe disease reactivation in four patients with relapsing-remitting multiple sclerosis after fingolimod cessation.

    Berger B, Baumgartner A, Rauer S, et al.

    Journal of neuroimmunology 2015; (282()):118-22.

    PMID: 25903738
  14. 14

    Repository corticotropin injection in multiple sclerosis: an update.

    Kutz CF, Dix AL

    Neurodegenerative disease management 2018; (8(4)):217-225 doi:10.2217/nmt-2018-0008.

    PMID: 29869572

This page explains long-term monitoring and warning signs in relapsing-remitting multiple sclerosis for informational purposes only and does not constitute medical advice. Contact your neurology team for individualized guidance, and call emergency services for severe or sudden symptoms.